Table 3

AUCs of blood phosphorylated tau (P-tau) in distinguishing between Aβ+ and Aβ− participants

P-tau1810.88CU young adults+CU elderly+MCI+ AD+FTDSimoa 48
0.84CU+MCI (CIND)+AD+VaDSimoa 51
0.76CU+MCI+ AD+non-ADSimoa 45
0.79CU+MCI+ AD+non-ADMSD 52
0.82CU+ADMSD 87
0.95CU young+CU elderly+MCI+ AD (discovery cohort)IP-MS 47
0.72CU+MCI+ AD (validation cohort)
0.77CUSimoa 48
0.70CUSimoa 55
0.77CUSimoa 46
0.72CUSimoa 30
0.70CUMSD 54
0.86CUMSD 53
0.67CU (validation cohort)IP-MS 47
0.74MCISimoa 48
0.80MCISimoa 55
0.82MCI (CIND)Simoa 51
0.75MCISimoa 46
0.85MCIMSD 54
0.94MCIMSD 53
0.68MCI (validation cohort)IP-MS 47
0.80CU+MCI (CIND)Simoa 51
0.71CU+MCI+prior neurological conditionsSimoa 30
0.75CU+MCIMSD 54
0.81CU+MCIMSD 52
P-tau2170.87CU+MCI+ AD+non-ADMSD 45
0.84CU+ADMSD 87
0.99CU young+CU elderly+MCI+ AD (discovery cohort)IP-MS 47
0.93CU+MCI+ AD (validation cohort)
0.86CU (validation cohort)
0.93MCI (validation cohort)
P-tau2310.83CUSimoa 46
  • Aβ, amyloid-β; AD, Alzheimer’s disease; AUC, area under the receiver operating characteristic curve; CIND, Cognitively impaired no dementia; CU, Cognitively unimpaired; FTD, Frontotemporal dementia; FTLD, Frontotemporal lobar degeneration; IP-MS, immunoprecipitation-mass spectrometry; MCI, mild cognitive impairment; MSD, Meso Scale Discovery; Simoa, single molecule array; VaD, Vascular dementia.